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Abstract
Background: Oxidative stress, an increase in oxidants and/or a decrease in antioxidant capacity,
is one of the potential biochemical mechanisms involved in the pathogenesis of nonalcoholic
steatohepatitis. We aimed to investigate the total antioxidant response using a novel automated
method in nonalcoholic steatohepatitis subjects. As a reciprocal measure, we also aimed to
determine total peroxide level in the same plasma samples.
Methods: Twenty-two subjects with biopsy proven nonalcoholic steatohepatitis and 22 healthy
controls were enrolled. Total antioxidant response and total peroxide level measurements were
done in all participants. The ratio percentage of total peroxide level to total antioxidant response
was regarded as oxidative stress index.
Results: Total antioxidant response of subjects with nonalcoholic steatohepatitis was significantly
lower than controls (p < 0.05), while mean total peroxide level and mean oxidative stress index
were higher (all p < 0.05).
In subjects with nonalcoholic steatohepatitis, fibrosis score was significantly correlated with total
peroxide level, total antioxidant response and oxidative stress index (p < 0.05, r = 0.607; p < 0.05,
r = -0.506; p < 0.05, r = 0.728, respectively). However, no correlation was observed between
necroimflamatory grade and those oxidative status parameters (all p > 0.05).
Conclusion: Nonalcoholic steatohepatitis is associated with increased oxidant capacity, especially
in the presence of liver fibrosis. The novel automated assay is a reliable and easily applicable method
for total plasma antioxidant response measurement in nonalcoholic steatohepatitis.
Background
Non-alcoholic fatty liver disease (NAFLD) is increasingly
recognized as a significant cause of morbidity in devel-
oped countries. NAFLD represents a spectrum of liver dis-
ease ranging from bland steatosis to severe steatohepatitis.
The prevalence of non-alcoholic steatohepatitis (NASH) is
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2.1–6.3% in the general population, rising to 9–40% in
obese individuals with a body mass index (BMI) of 30 kg/
m2  or more. Steatohepatitis can be progressive, cause
fibrosis and cirrhosis, and can ultimately lead to liver fail-
ure and hepatocellular carcinoma in a minority of
patients [1-4].
The pathogenesis of NASH remains unclear and the fac-
tors, which cause the progression from bland steatosis to
steatohepatitis, often termed the 'second hit', remain
poorly understood [5-7]. One potential biochemical
mechanism of pathogenesis of NASH is oxidative stress
[8,9]. Oxidative stress is a cardinal feature of alcoholic
steatohepatitis [10]. Histological similarity between
NASH and alcohol induced liver disease suggests some
shared pathogenetic features such as oxidative stress and
cytokine-mediated injury [5-8,11,12]. In addition, evi-
dence of oxidative stress have been found in human livers
showing steatosis or NASH [13], and in experimental
models of NASH [14]. The efficacy of several antioxidant
agents on hepatic steatosis, inflammation, and fibrosis in
subjects with NASH has been investigated in several small,
open-label studies [15-17]. In all of these studies, those
antioxidant agents exerted beneficial effects in improving
necroinflammatory activity or fibrosis or both. These find-
ings are also suggestive for the role of oxidative stress in
the pathogenesis of NASH.
Various methods have been developed for the measure-
ment of total antioxidant status. However, there is not yet
an accepted "gold standard" reference method [18], and
decisions concerning standardization, and the terms and
units used for the measurement of total antioxidant
response (TAR) [19]. This implies that this topic needs to
be studied further [20].
In the present study, we aimed to measure TAR using a
novel automated method in NASH subjects [20]. As a
reciprocal measure, the total peroxide levels were also
measured at the same plasma samples. The ratio percent-
age of the total plasma peroxide level to the plasma TAR
value was regarded as oxidative stress index (OSI) [21].
Methods
Enrollment of patients
Twenty-two subjects with biopsy proven NASH (19 male,
3 female; mean age, 37.7 ± 8.8) and 22 healthy controls
(17 male, 5 female; mean age, 34.6 ± 9.3) were enrolled
in the present study. The study protocol was approved by
the local research committee for ethics. All subjects were
informed about the study and the written consent was
obtained from each one.
Initial evaluation
The major indications for liver biopsy in those 22 subjects
were ultrasonographically diagnosed fatty liver and eleva-
tion in alanine aminotransferase (ALT).
Diagnosis of NASH was made according to the following
criteria:
- Existence of hepatic steatosis (≥10% of hepatocytes
affected) with acinar zone 3 hepatocellular injury (bal-
looning degeneration) and/or lobular inflammation, with
or without Mallory's hyaline and pericellular and/or sinu-
soidal fibrosis, on liver byopsy, which was performed
within the previous 12 months. Necroimflamatory grad-
ing and fibrosis scoring were based on a modification of
the scoring system proposed by Brunt et al [3].
- Negative serological markers for viral infection such as
HBsAg, anti-HCV or anti-HIV, and immunological disor-
ders such as antinuclear anti-bodies, anti-smooth muscle
antibodies, and anti-liver/kidney microsomes type 1 anti-
body.
- No evidence that favor of metabolic liver disease such as
Wilson's disease and hemochromatosis and alpha-1 anti-
trypsin deficiency.
Necroimflamatory grades and fibrosis scores of the 22
subjects with NASH were as follows:
- Grade 1 (mild) necroimflamatory changes, in 5
(22.73%) subjects; grade 2 necroimflamatory changes
(moderate), in 12 (54.54%) subjects; grade 3 necroim-
flamatory changes, in 5 (22.73%) subjects.
- Stage 0 Zone 3 perisinusoidal/pericellular fibrosis, in 2
(9.1%) subjects; stage 1, in 9 (40.9%) subjects; stage 2, in
9 (40.9%) subjects; stage 3, in 2 (9.1%) subjects.
- None of the subjects with NASH had stage 4 fibrosis.
Exclusion criteria
Exclusion criteria included recent gastrointestinal by-pass
surgery, pregnancy, serum total bilirubin level higher than
2 mg/dL, usage of esterogens, tamoxifen, glucocoticoids,
usage of supplemental vitamins, calcium-channel block-
ers, aspirin, amiodarone, and methotrexate in the previ-
ous 6 months, existence of diabetes mellitus, coronary
artery disease, rheumatoid arthritis, cancer, systemic or
local infection, and history of excess alcohol ingestion,
averaging more than 30 gm/day (3 drinks per day) in the
previous 10 years, or history of alcohol intake averaging
greater than 10 gm/day (1 drink per day: 7 drinks per
week) in the previous 1 year.BMC Gastroenterology 2005, 5:35 http://www.biomedcentral.com/1471-230X/5/35
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Recently, it has been suggested that oxidative stress itself
may play a crucial role in pathogenesis of diabetes melli-
tus [22]. Additionally, both increase in oxidative stress
and decrease in antioxidant capacities could be related to
the complications of diabetes mellitus [23]. Thus, in the
present study, we excluded the subjects with diabetes mel-
litus in order to reflect the accurate role of oxidative stress
in pathogenesis NASH.
The clinical and demographic data of the study groups
were shown in Table 1.
Blood collection
Blood samples were obtained in fasting state. Samples
were withdrawn from a cubital vein into heparinised
tubes and immediately stored on ice at 4°C. Then, the
plasma was separated from the cells by centrifugation at
3000 rpm for 10 min, and the plasma samples were stored
at -80°C until analysis.
Measurement of the total antioxidant status of plasma
The total antioxidant status of the plasma was measured
using a novel automated colorimetric measurement
method for TAR developed by Erel [20]. In this method,
the hydroxyl radical, the most potent biological radical, is
produced by the Fenton reaction, and reacts with the col-
ourless substrate O-dianisidine to produce the dianisyl
radical, which is bright yellowish-brown in colour. Upon
the addition of a plasma sample, the oxidative reactions
initiated by the hydroxyl radicals present in the reaction
mix are suppressed by the antioxidant components of the
plasma, preventing the colour change and thereby provid-
ing an effective measure of the total antioxidant capacity
of the plasma. The assay results are expressed as mmol
Trolox eq./L, and the precision of this assay is excellent,
being lower than 3% [24].
Measurement of total plasma peroxide concentration
The total plasma peroxide concentrations were deter-
mined using the FOX2 method [25] with minor modifica-
tions [21]. The FOX2 test system is based on the oxidation
of ferrous iron to ferric iron by the various types of perox-
ides contained in the plasma samples, in the presence of
xylenol orange which produces a coloured ferric-xylenol
orange complex whose absorbance can be measured. The
FOX2 reagent was prepared by dissolving ammonium fer-
rous sulphate (9.8 mg) in 250 mM H2SO4 (10 ml) to give
a final concentration of 250 mM ferrous iron in acid. This
solution was then added to 90 ml HPLC-grade methanol
containing 79.2 mg butylated hydroxytoluene (BHT).
Finally, 7.6 mg xylenol orange was added, with stirring, to
make the working reagent (250 mM ammonium ferrous
sulphate, 100 mM xylenol orange, 25 mM H2SO4, and 4
nM BHT, in 90% (v/v) methanol in a final volume of 100
ml). The blank reagent contained all the components of
the solution except ferrous sulphate. Aliquots (200 mL) of
plasma were mixed with 1.8 ml FOX2 reagent. After incu-
bation at room temparature for 30 min, the vials were cen-
trifuged at 12,000 g for 10 min. The absorbance of the
supernatant was then determined at 560 nm. The total
peroxide content of the plasma samples was determined
as a function of the difference in absorbance between the
test and blank samples using a solution of H2O2 as stand-
ard. The coefficient of variation for individual plasma
samples was less than 5%.
Oxidative stress index
The ratio percentage of the total peroxide to the total anti-
oxidant potential gave the oxidative stress index, an indi-
cator of the degree of oxidative stress [21].
Statistical analysis
Data were presented as mean ± SD. Continuous variables
were compared using Student t test. Qualitative variables
were tested by Chi-square test. Spearman correlation test
was used to find out the correlation of fibrosis scores and
necroinflamatory grades with total preroxide level, OSI or
TAR. Correlations of serum triglyceride and cholesterol
levels with total peroxide level, OSI or TAR were analyzed
using Pearson correlation test. p < 0,05 was considered as
statistical significance.
Results
Two groups were comparable for age, BMI, gender distri-
bution and smoking habit (p value was >0.05 for each
comparison). Serum triglyceride and cholesterol levels
were significantly higher in subjects with NASH than con-
trols (p value was >0.05 for each comparison).
TAR was 0.85 + 0.11 and 1.88 + 0.32 mmol Trolox eq./L
in subjects with NASH and controls, respectively (p <
0.05). Total plasma peroxide level of subjects with NASH
and controls was 53.3 + 7.7 and 33.0 + 14.2 µmol H2O2/
L, respectively (p < 0.05). OSI was 0.64 + 0.14 and 0.19 +
Table 1: The clinical and demographic data of the study groups
Subjects with NASH Control subjects
Age 37.7 ± 8.8 34.6 ± 9.3
Weight 83.5 ± 9.4 80.7 ± 14.5
Height 171.1 ± 5.8 169 ± 7.8
BMI 28.9 ± 3 27.7 ± 3.3
Triglyceride 228 ± 93.7* 159.8 ± 62.6
Cholesterol 205.4 ± 44.4* 168.5 ± 35.1
ALT 70 ± 29 23 ± 6
Smoking habit 14 (63.6%) 11 (50%)
Data were presented as mean ± SD.
*p<0.05 vs. controls.
ALT, Alanine Aminotransferase; BMI, Body Mass Index.BMC Gastroenterology 2005, 5:35 http://www.biomedcentral.com/1471-230X/5/35
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0.11 AU in subjects with NASH and controls, respectively
(p < 0.05).
Total peroxide level and OSI were positively correlated
with serum triglyceride level in subjects with NASH (p <
0.05, r = 0.432; p < 0.05, r = 0.521, respectively), while no
correlation with serum cholesterol level (p > 0.05 for each
comparison). Serum triglyceride and cholesterol levels
were not correlated with both total peroxide level and OSI
value in control subjects (p > 0.05 for each comparison).
No correlation was observed between TAR, and serum
triglyceride and cholesterol level in both NASH subjects
and controls (p > 0.05 for each comparison).
Fibrosis scores of subjects with NASH were positively cor-
related with total peroxide level and OSI (p < 0.05, r =
0.607 and p < 0.05, r = 0.728, respectively) (Fig 1, 2),
while negatively correlated with TAR (p < 0.05, r = -0.506)
(Fig 3). No significant correlation was observed between
necroimflamatory grades, and total peroxide level, TAR
and OSI (p value was >0.05 for each comparison).
Discussion
Steatosis of the liver is mediated by a multiple factors such
as increase in dietary fat intake, release of free fatty acids
(FFA) from adipose tissue, insufficient hepatic lipid secre-
tion, and development of insulin resistance [26]. FFA oxi-
dation, CYP2E1 induction, leukocyte infiltration and
activation of NADPH oxidase, and mitochodrial dysfunc-
tion involving electron transfer inhibition in the respira-
tory chain increase the production of reactive oxygen
species (ROS) such as singlet oxygen, superoxide anion,
hydrogen peroxide, and hydroxyl radical [10].
In the present study, in subjects with NASH, significant
increases in both total peroxide level and OSI were accom-
panied with significant decreases in TAR compared to
control subjects. In the presence of increased total perox-
ide level, a decrease in TAR indicates to a high degree of
oxidative stress. In addition, in subjects with NASH, total
peroxide level and OSI showed positive correlation with
fibrosis score. In contrast, TAR showed negative correla-
tion with TAR. On the basis of these findings, it can also
be suggested that oxidative stress may have a role in the
progression of steatohepatitis to liver fibrosis.
In order to reflect the true state of oxidative stress in the
liver, it is more ideal to measure lipid peroxidation mark-
ers and antioxidant components in hepatic tissue. Never-
theless, it is impossible to perform multiple tests on very
limited amounts of biopsy specimen that obtained in nee-
dle biopsy. In addition, liver biopsy carries a significant
morbidity and even mortality risk. It is not an ethical
approach to perform liver biopsy in healthy controls to
provide a comparison with NASH subjects. Thus, in the
present study, we have chosen to measure TAR and total
peroxide level in plasma samples.
In a few studies, in NASH subjects, antioxidant and oxi-
dant capacities have been investigated [27-29]. Koruk et al
[27] reported an increase in oxidative stress in NASH sub-
jects. However, in their study, plasma anitoxidant capaci-
ties observed to be comparable in NASH subjects and
controls. They suggested that impaired antioxidant
defense mechanisms in responding to increased oxidative
stress might be an important factor in the pathogenesis of
NASH. In a study of Fierbinteanu-Braticevici et al [28],
serum index of oxidative stress have been suggested as an
independent risk factor for fibrosis in the course of NASH.
In a recent study, which was conducted by Videla et al
[29], it has been shown that NAFLD patients with steato-
sis exhibit a substantial pro-oxidant condition in the liver
at early stages of steatosis. This pro-oxidant condition was
observed to occur concomitantly with a significant
decrease in hepatic SOD activity, changes involving an
overall derangement in the antioxidant status of the liver,
with the consequent diminution in the antioxidant capac-
ity of plasma. They also observed that further exacerbation
in oxidative stress was associated with CYP2E1 induction
in patients with steatohepatitis.
Various antioxidants have additive effects on oxidative
status. In human serum, the cooperation of these antioxi-
dants protects the organism against the attacks by free rad-
icals [30]. Although the concentration of plasma
Correlation between serum total peroxide levels and the  score of liver fibrosis among nonalcoholic steatohepatitis  group Figure 1
Correlation between serum total peroxide levels and the 
score of liver fibrosis among nonalcoholic steatohepatitis 
group.BMC Gastroenterology 2005, 5:35 http://www.biomedcentral.com/1471-230X/5/35
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antioxidant components can be measured individually,
these measurements may be time- and cost-consuming
and labour intensive. In addition, it may not accurately
reflect the total antioxidant status [24]. Thus, the accurate
antioxidant capacity of the organism can only be deter-
mined by the measurement of TAR [19,20].
In concordance with the study of Videla et al [29], in the
present study, we determined the antioxidant capacity
using TAR measurement. The oxidants and antioxidant
capacity were determined simultaneously to evaluate oxi-
dative stress accurately. However, in study of Videla et al.
[29], TAR measurement was performed using ferric reduc-
ing ability of plasma (FRAP), while a novel automated
method in our study.
The most widely used methods for TAR measurement are
colorimetric, fluorescence, and chemiluminescence [31-
33]. The fluorescence and chemiluminescence methods
need sophisticated techniques and, in most routine clini-
cal biochemistry laboratories, these improved systems are
not present. Randox- total antioxidant status (TAS) assay
and FRAP assay are the widely used colorimetric TAR
measurement methods. In the FRAP assay, the reference
range of serum TAR is lowest because this assay practically
measures non-protein total antioxidant capacity. How-
ever, proteins constitute the main antioxidant component
of serum (plasma). The Randox-TAS assay can determine
the antioxidative effects of bilirubin, vitamin C, uric acid,
polyphenols, and proteins; hence, the reference range for
serum TAR is higher than that for the FRAP assay. The
novel method is more sensitive for determining the anti-
oxidative effects of bilirubin, uric acid, vitamin C,
polyphenols, and proteins. Hence, serum TAR measured
by the novel method is higher than those of the Randox-
TAS and FRAP assays [20].
In addition, the novel method, which was used in the
present study, provides further several advantages in com-
parison with other currently available methods. It is sim-
ple and cheap, and can easily be fully automated. It also
does not interact with commonly occurring serum com-
ponents such as bilirubin, serum lipids, and anticoagu-
lants. Accurate measurements of TAR can be obtained
within approximately 10 minutes, making this assay emi-
nently suitable for the clinical biochemistry laboratory
[20].
Conclusion
NASH is associated with increased oxidant capacity, espe-
cially in the presence of liver fibrosis. The novel auto-
mated calorimetric assay is a useful, reliable, simple and
easily applicable method in the assessment of the total
plasma antioxidant response in NASH.
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